Company / Operating Cash Flow per Share
MoonLake Immunotherapeutics Operating Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.04
FY2025
5-year range
-$4.49 / -$0.87
FY2021-FY2025
Trend
-64.0%
vs FY2024
Sector context
#169 of 212
Health Care
What the data says
MoonLake Immunotherapeutics's operating cash flow per share of $-3.04 is lower than 80% of companies in the Health Care sector (FY2025). Declined from $-0.87 to $-3.04 over the past 2 years.
Based on SEC 10-K filings.
-3.04 in FY2025.
Declined from $-0.87 to $-3.04 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 212This company -$3.04 Sector average -$14.72
▼
+79.3% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 64.0% year-over-year.
- Ranks #169 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2020.
- Lowest operating cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.04 | -64.0% |
| FY2024 | -$1.85 | -112.9% |
| FY2023 | -$0.87 | +54.3% |
| FY2022 | -$1.90 | +57.6% |
| FY2021 | -$4.49 | -8728.3% |
| FY2020 | -$0.05 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026